ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $12.50.

Several research analysts have recently issued reports on ALXO shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Monday, August 12th. UBS Group dropped their price target on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Lifesci Capital lowered ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Redmile Group LLC lifted its stake in shares of ALX Oncology by 18.2% in the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock valued at $48,241,000 after purchasing an additional 667,245 shares during the period. Marshall Wace LLP lifted its stake in ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after buying an additional 514,133 shares during the period. Privium Fund Management B.V. bought a new position in shares of ALX Oncology during the 2nd quarter worth approximately $2,271,000. Point72 Asset Management L.P. acquired a new stake in shares of ALX Oncology during the 2nd quarter worth approximately $1,834,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of ALX Oncology in the 3rd quarter valued at $469,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Stock Down 1.3 %

Shares of NASDAQ:ALXO opened at $1.51 on Friday. ALX Oncology has a 52-week low of $1.34 and a 52-week high of $17.83. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average of $1.80 and a 200-day moving average of $6.21.

ALX Oncology (NASDAQ:ALXO) last issued its earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01. Analysts forecast that ALX Oncology will post -3.04 EPS for the current year.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.